期刊
JOURNAL OF CLINICAL MEDICINE
卷 11, 期 19, 页码 -出版社
MDPI
DOI: 10.3390/jcm11195669
关键词
inflammatory bowel disease; infliximab; vedolizumab
This study retrospectively investigated the uptake and rationale for switching from intravenous infusions to subcutaneous injections of infliximab (IFX) or vedolizumab (VDZ) for inflammatory bowel disease (IBD) treatment. The results showed that approximately 58% of IFX patients and VDZ patients chose to switch to subcutaneous treatment, and the decision to switch was not influenced by demographic or clinical factors. Questionnaire responses revealed that time savings were the primary motivator for patients to switch.
Background: Recent trials support the clinical efficacy and safety of subcutaneous infliximab (IFX) or vedolizumab (VDZ) for Inflammatory Bowel Disease (IBD). We evaluated the uptake and rationale for choosing to switch from intravenous infusions to subcutaneous injections. Methods: Retrospective analysis of all adult patients receiving standard dosing IFX or VDZ maintenance therapy to investigate uptake of subcutaneous injections and the rationale for switching to subcutaneous injections. Results: Of 232 eligible patients (total = 258: IFX = 190, VDZ = 68, and no longer eligible = 26), 58% of patients on IFX and 59% of patients on VDZ chose to switch to subcutaneous treatment. Age, sex, diagnosis, drug, line of treatment, and duration of treatment were not predictors for willingness to switch. Questionnaire responses (n = 51) demonstrate that the decision to switch was not influenced by COVID-19 exposure risk, impact on wider IBD service provision, impact on patient mental health, financial savings, seeking support following a switch, or a sense of independence managing IBD. Switchers (68%) were more motivated by time savings than non-switchers (25%; p = 0.0042). Conclusions: Switch uptake rates were 58%, with 90% of patients eligible to switch. Switch decision was influenced by time savings for patients but not by other patient-related factors.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据